Univ.-Prof. Dr. med. Marion Subklewe

• Director of the Munich Center for Cell and Gene Therapy
  
• Consultant in the Department of Hematology/Oncology, Medizinische Klinik und Poliklinik III, LMU Medizin, Munich
  
• Laboratory for Translational Cancer Immunology, Gene Center, LMU
  

• Degree: Study of Medicine at the University of Aachen and the University of Cologne

  Doctorate: Internal Medicine with focus on Hematology/Oncology, University of Cologne

  Medical Boards: Internal Medicine (2005), Hematology and Internal Oncology (2007)

  2007: Habilitation in Internal Medicine, Charité, "Development of immunotherapeutic approaches for EBV-associated malignancies"

  2014: W2 Professorship in Internal Medicine with focus on Cellular Therapy, LMU Munich

• Member of the Walter Siegenthaler Gesellschaft
  
• Member of the LMU-KUM Faculty Council (2023)
  
• Member of the Research Strategy Committee ("Forschungskommission")
  
• Speaker of the LMU Munich site within the SFB-TR338 (TUM and Würzburg)
  
• Speaker of the Medical & Clinician-Scientist Program of the LMU Medical Faculty
  
• Founder and Speaker of "FAME" (Female Academia Medicine Excellence), a consortium of female professors at the Medical Faculty of the LMU
  
• Member of the DFG Fachkollegium (Hämatologie/Onkologie)
  
• Member of the Deutsche Krebshilfe section "Med./Wiss. Nachwuchsförderung"
  
• Member of the Deutsche Krebshilfe CCC Network expert group "Immunonkologie"
  
• Member of the Scientific Advisory Board of the José Carreras Foundation
  
• Head of the "Molecular Oncology" module within the Elite Master Program Human Biology – Principles in Health & Disease of the Faculties of Biology and Medicine, LMU
  
• Member of the steering committee of "GO-CART", a joint consortium of EHA and EBMT
  
• Member of the steering and organizing committee of the International Symposium "Acute Leukemias" and of iTOC (Immunotherapy of Cancer)
  

Collaborative research activities: Deutsches Konsortium für Translationale Krebsforschung (DKTK); Bayerisches Zentrum für Krebsforschung (BZKF); SFB-TR338 initiative "T cell engineering"; JÖSTER Stiftung, CAR 360 degree, a collaborative project of the LMU; Marie Skłodowska-Curie doctoral network "MIRACLE" (funded by the European Union's Horizon Europe programme); MetaboTargetAML project (funded by the European Partnership for Personalised Medicine, EP PerMed, under the European Union's Horizon Europe programme, grant agreement no. 101137129)

Grant reviews: Deutsche Forschungsgemeinschaft; Deutsche Krebshilfe; José Carreras Stiftung; Wilhelm Sander Stiftung; Cancer Research UK; Leukemia and Lymphoma; OeGHO; Dutch Cancer Society; Worldwide Cancer Research

Editorial work and manuscript reviews: Editor of EJC; Editor of Blood Immunology and Cellular Therapy; Editorial Board of Blood; reviewer for Nature, Science, Cell, Leukemia, Lancet Hematology, NEJM, PLOS ONE, J International Immunology, Journal of Hematology & Oncology, Haematologica, British Journal of Hematology, Journal of Immunotherapy, Oncoimmunology, Oncotarget, Blood Reviews, Blood Advances

Memberships: Bund deutscher Internisten (BdI); European Association for Hematology (EHA); American Society for Hematology (ASH); Deutsche Gesellschaft für Hämatologie und Onkologie (DGHO); Society for Immunotherapy of Cancer (SITC)

• Highly Cited Researcher 2024, 2025
  
• HemaSphere Award 2025, Top Cited Clinical Article
  
• EHA Educational Presentation 2021, 2022, 2023, 2025, 2026
  
• Pfleger Preis 2024
  
• ASH Educational (CART Tox) 2023
  
• ASH Educational (AML) 2023
  
• Grand Rounds MD Anderson Cancer Center 2018, 2020, and Moffitt Cancer Center 2022
  
• ASH Abstract Achievement Awards 2011, 2016, 2018, 2020–2025
  
• M4 Award 2015: startup support for the development of novel multifunctional antibodies
  
• Therese von Bayern-Award 2012
  
• Best Lecturer at the Faculty of Medicine at the LMU 2011
  
• Rahel-Hirsch Scholarship 2005–2007 at the Charité
  
• Cure for Lymphoma Foundation Fellow 1999–2000
  
• Scholarship of the DFG 1996–1999
  

• Head of the Immunotherapy Program, LMU University Hospital Munich
  
• Head of the CAR T Program, LMU University Hospital Munich
  
• Head of the Core Facility "iFLOW" at the Medical Faculty of the University Hospital Munich
  
• Head of the Flow Cytometry & Sorting unit within the Leukemia Diagnostics lab (certified 2011, accredited 2012)
  
• Founder and Speaker of the national "Harmonize MRD Flow" Consortium
  
• Founder and Speaker of the harmonization of "CART Quantification" of the DGHO AK Labormedizin
  
• Member of the ELN Working Group "MRD"
  
• Member of the Hematological Board Committee; Member of the Toxboard Immuno-oncology; Head of the CART Board Committee
  

Principal Investigator in more than 50 oligo- and multicentric Phase I/II/III trials (CAR T, T-cell recruiting antibodies, monoclonal antibodies, immunochemotherapy, small molecules) in leukemia, lymphoma, GI tumors, multiple sclerosis and other autoimmune diseases.

Investigator-initiated trials

• ERASE: Rezeptor-aktivierte, in vitro stimulierte T-Zellen für Hochrisiko-AML (BZKF)
  
• A phase I first-in-human study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of CD33-targeted Adapter-CAR T cells for the treatment of adult patients with R/R AML (BMBF)
  
• AARON Study: An open-label phase II study of relatlimab (BMS-986016) with nivolumab (BMS-936558) in combination with 5-azacytidine for the treatment of patients with R/R AML and newly diagnosed AML
  
• DLI Target: Donor lymphocyte infusion plus blinatumomab
  
• New generation dendritic cell vaccine for immunotherapy in AML (BayImmunet)
  

Further trials

• A phase 2, open-label, single-arm, multicohort, multicenter trial to evaluate the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory indolent B-cell non-Hodgkin lymphoma (Transcend FL). Celgene Corporation; Phase II
  
• A global randomized multicenter phase 3 trial to compare the efficacy and safety of JCAR017 to standard of care in adult subjects with high-risk, transplant-eligible relapsed or refractory aggressive B-cell non-Hodgkin lymphomas (Transform). Celgene Corporation; Phase III
  
• A phase 1/2 multicenter study evaluating the safety and efficacy of KTE-X19 in adult subjects with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL). Gilead; 2015-005009-35; Phase I/II
  
• A phase I/II safety, dose finding and feasibility trial of MB-CART19.1 in patients with relapsed or refractory CD19-positive B-cell malignancies. Miltenyi Biotec GmbH; Phase I/II
  
• A phase 1 first-in-human study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of AMG 427 in subjects with relapsed/refractory acute myeloid leukemia. Amgen; 2018-001389-40; Phase I
  
• A phase 1 first-in-human study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of AMG 673 administered as short-term intravenous infusions in subjects with relapsed/refractory acute myeloid leukemia. Amgen Inc.; 2017-002980-16; Phase I
  
• A phase 1 first-in-human study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of AMG 330 administered as continuous intravenous infusion in subjects with relapsed/refractory acute myeloid leukemia. Amgen Inc.; 2014-004462-20; Phase I
  
• An open-label, multicenter, phase 1b study of JNJ-74494550 (cusatuzumab; anti-CD70 monoclonal antibody) in combination with background therapy for the treatment of subjects with acute myeloid leukemia. Janssen; 2019-002808-41; Phase I
  
• A phase 1, first-in-human, dose escalation study of JNJ-67571244 (bispecific antibody targeting CD33 and CD3) in subjects with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Janssen-Cilag; 2018-004452-37; Phase I
  
• A phase II trial for the treatment of older patients with newly diagnosed CD19-positive, Ph/BCR-ABL-negative B-precursor acute lymphoblastic leukemia with sequential dose-reduced chemotherapy and blinatumomab. University Frankfurt am Main; 2017-002853-13; Phase II
  
• Therapieoptimierung bei erwachsenen Patienten mit neu diagnostizierter akuter lymphatischer Leukämie (ALL) oder lymphoblastischem Lymphom (LBL) durch individualisierte, gezielte und intensivierte Therapie. University Frankfurt am Main; 2013-003466-13; Phase III
  
• A multicenter, single-arm study to assess the efficacy, safety and tolerability of the BiTE antibody blinatumomab in adult patients with minimal residual disease (MRD) of B-precursor acute lymphoblastic leukemia (Blast Successor Trial). University Frankfurt am Main; 2015-000733-76; Phase II
  
• Midostaurin + gemtuzumab ozogamicin combination in first-line standard therapy for acute myeloid leukemia (MOSAIC). Technische Universität Dresden; 2019-03863-23; Phase I/II
  
• A double-blind, placebo-controlled, randomized, multicenter phase II study to assess the efficacy of BL-8040 addition to consolidation therapy in AML patients. Martin-Luther-University Halle-Wittenberg; 2014-002702-21; Phase II
  
• A phase II randomized, open-label, multicenter study of the safety and efficacy of IMCgp100 compared with investigator's choice in HLA-A*0201-positive patients with previously untreated advanced uveal melanoma. Immunocore, Ltd.; 2015-003153-18; Phase II
  
• A phase 3, multicenter, double-blind, randomized, placebo-controlled study of AG-120 in combination with azacitidine in subjects older than 18 years of age with previously untreated acute myeloid leukemia with an IDH1 mutation. Agios Pharmaceuticals; 2016-004907-30; Phase III
  
• A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia. Roche; 2020-001154-22; Phase III
  
• First-in-man study with MEN1112, a CD157-targeted monoclonal antibody, in relapsed or refractory acute myeloid leukemia. Menarini Ricerche S.p.A.; 2014-002433-59; Phase I
  
• A phase 3, multicenter, randomized, open-label study of guadecitabine (SGI-110) versus treatment choice in adults with previously treated acute myeloid leukemia. Astex Pharmaceuticals; 2015-005256-97; Phase III